Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with or without BEZ235 to enhance influenza vaccine response in older adults at risk for respiratory infections
ACTRN12618000365268Phase 2Completed
- Sponsor
- resTORbio
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza and Airways Infection comparing Group A everolimus with Group A everolimus + BEZ235 (2 arms). Primary endpoint: Change in hemagglutination inhibition geometric mean titers. Started May 2018; status: completed.
02
Drugs
everolimusdactolisib
03
Conditions
influenzaAirways Infection
Beyond the preview
Go deeper on ACTRN12618000365268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000365268.